Daraxonrasib Toxicity Prevention and Management

Authored by Open Medicine, published on 2026-08-30 18:15:00.0

This algorithm is broadly aligned with current practice for managing adverse events of targeted oral therapies, and it closely follows the daraxonrasib (RASONQUE) FDA label for dosing, holds, dose reductions, and key serious risks (ILD/pneumonitis, GI perforation) in metastatic pancreatic adenocarcinoma. The core toxicity pathways (rash, stomatitis, diarrhea) and the dose-reduction ladder mirror prescribing-information-directed approaches and are consistent with CTCAE-based grading. The prophylaxis steps (skin regimen; consideration of tetracycline-class antibiotics) are reasonable and commonly used for acneiform/EGFR-like rashes, though evidence for prophylaxis may be extrapolated and not always trial-mandated for this agent.

  1. Confirm mPDAC after prior therapy or when multiagent therapy is unsuitable
    FDA-approved for metastatic pancreatic adenocarcinoma after ≥1 prior systemic therapy or when multiagent systemic therapy is not appropriate. The U.S. indication is not restricted by RAS mutation status and does not require a companion diagnostic.
    • Baseline: CBC/CMP, Mg/Ca, LFTs, CA 19-9 + skin/oral/GI assessment
      Before first dose: • CBC with differential and platelets.• CMP including sodium, potassium, creatinine/eGFR and glucose.• Liver profile: AST, ALT, ALP, total bilirubin and albumin.• Corrected calcium and magnesium.• CA 19-9. Interpret together with bilirubin and biliary obstruction/stent status.• Pregnancy test when applicable. Clinical baseline:• Weight and ECOG performance status.• Skin and oral examination.• Baseline bowel function, oral intake and hydration. If CA 19-9 is uninformative, consider CEA for disease monitoring.
      • Before first dose: review CYP3A/P-gp and drug interactions adjust daraxonrasib if needed. Review concomitant medications
        Avoid strong CYP3A inhibitors with P-gp inhibition and systemic cyclosporine A. Other strong/moderate CYP3A inhibitors and P-gp inhibitors require label-directed daraxonrasib dose adjustment. Avoid strong CYP3A inducers when possible; dose adjustment is required if unavoidable. Separate P-gp substrates from daraxonrasib by at least 4 hours. Do not use the adverse-reaction 300→200→150 mg dose ladder for drug interactions; interaction-specific doses are different.
        • Before first dose: topical corticosteroid + emollient + SPF ≥30; consider doxycycline/minocycline
          Start dermatologic prophylaxis before the first dose and continue during treatment as clinically appropriate: Apply a topical corticosteroid to the face and chest. Use emollient creams. Limit sun exposure. Use broad-spectrum sunscreen SPF ≥30. Consider prophylactic oral doxycycline or minocycline.
          • Start daraxonrasib 300 mg once daily — with or without food; swallow tablets whole
            Take daraxonrasib at the same time each day. Swallow tablets whole; do not chew, crush or split. If a dose is missed by >4 hours, skip it and take the next dose at the regularly scheduled time. If vomiting occurs after a dose, do not take an additional dose.
            • First 8 weeks: repeat CBC/CMP/LFTs, Mg/Ca about q2 weeks; then q4 weeks if stable
              Practical monitoring schedule: • Repeat CBC, renal/electrolyte profile, AST/ALT/ALP/bilirubin/albumin, corrected calcium and magnesium approximately every 2 weeks during the first 8 weeks. • If stable, repeat approximately every 4 weeks thereafter. • Check sooner for significant diarrhea, reduced oral intake, dehydration, new toxicity or prior laboratory abnormalities. • Repeat CA 19-9 with disease-response assessments; interpret trends rather than isolated values and do not use CA 19-9 as a substitute for imaging. The U.S. Prescribing Information does not mandate a fixed laboratory monitoring interval.
              • New or worsening toxicity requiring intervention?
                Assess CTCAE grade, symptom burden, oral intake/hydration, relevant laboratory abnormalities and serious red flags. Keep toxicity-specific grading within each branch rather than expanding the main flow.
                • Yes
                  • Rash / dermatologic toxicity. 87% overall; Grade 3–4 13%
                    Assess extent, symptoms, skin integrity and impact on daily activities. Dermatologic toxicity may include rash, pruritus, paronychia, dry skin and skin fissures. Median time to first onset: 13 days.
                    • Topical corticosteroid ± doxycycline/minocycline; modify daraxonrasib by grade
                      Continue or intensify topical corticosteroid and emollient therapy. If not already receiving an oral antibiotic, consider doxycycline or minocycline as clinically appropriate. RASolute protocol prophylaxis used doxycycline 100 mg twice daily or minocycline 50 mg twice daily. Grade 2: • Consider withholding daraxonrasib until recovery to ≤Grade 1. • Resume at the same or next lower dose. Grade 3: • Withhold until recovery to ≤Grade 1. • Consider dermatology consultation. • Resume at the next lower dose. Grade 4: • Permanently discontinue daraxonrasib.
                      • Does label guidance require treatment interruption or dose modification?
                        Applies to any toxicity requiring hold. Refer to dose reduction rules below.
                        • After recovery, which label-directed daraxonrasib disposition applies?
                          Most toxicity-specific restart criteria require recovery to ≤Grade 1; for other Grade 3 adverse reactions, recovery to ≤Grade 1 or baseline is required. Select the disposition specified for the toxicity and grade.
                          • Resume daraxonrasib at the current dose when label guidance permits
                            Applicable to selected Grade 2 rash, stomatitis or diarrhea after recovery to ≤Grade 1 when resumption at the same dose is clinically appropriate.
                            • Ongoing daraxonrasib monitoring at the tolerated dose
                              Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                          • Resume one dose level lower — 300 → 200 → 150 mg once daily
                            If recurrence or grade ≥2 intolerable, reduce dose How to dose reduce daraxonrasib: Starting dose: 300 mg once daily First reduction: 200 mg once daily (one 100 mg + one 100 mg) Second reduction: 150 mg once daily (one 150 mg) No further reduction below 150 mg Permanently discontinue if unable to tolerate 150 mg This ladder applies to adverse reactions; drug-interaction dose adjustments are different.
                            • Ongoing daraxonrasib monitoring at the tolerated dose
                              Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                          • Permanently discontinue daraxonrasib when required by toxicity-specific label guidance
                            Permanent discontinuation is required for specified severe or recurrent toxicities and when 150 mg once daily cannot be tolerated. Follow the toxicity-specific prescribing information.
                        • Continue daraxonrasib at current dose
                          • Ongoing daraxonrasib monitoring at the tolerated dose
                            Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                  • Stomatitis / oral toxicity. 56% overall; Grade 3–4 12%
                    Assess grade and impact: mouth pain, mouth soreness, dysgeusia, oral mucositis, oral intake and hydration. Median time to first onset: 22 days.
                    • Stomatitis: start dexamethasone mouthwash; modify daraxonrasib by grade
                      Continue oral care. Supportive regimen: • Dexamethasone 0.5 mg/5 mL mouthwash: 10 mL TID; swish and spit. No food or drink for 30 minutes after use. • Clotrimazole lozenge 10 mg TID. Daraxonrasib modification: • Grade 2: consider withholding until recovery to ≤Grade 1; resume at the same or next lower dose. • Grade 3: withhold until recovery to ≤Grade 1; resume at the next lower dose. • Grade 4: permanently discontinue.
                      • Does label guidance require treatment interruption or dose modification?
                        Applies to any toxicity requiring hold. Refer to dose reduction rules below.
                        • After recovery, which label-directed daraxonrasib disposition applies?
                          Most toxicity-specific restart criteria require recovery to ≤Grade 1; for other Grade 3 adverse reactions, recovery to ≤Grade 1 or baseline is required. Select the disposition specified for the toxicity and grade.
                          • Resume daraxonrasib at the current dose when label guidance permits
                            Applicable to selected Grade 2 rash, stomatitis or diarrhea after recovery to ≤Grade 1 when resumption at the same dose is clinically appropriate.
                            • Ongoing daraxonrasib monitoring at the tolerated dose
                              Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                          • Resume one dose level lower — 300 → 200 → 150 mg once daily
                            If recurrence or grade ≥2 intolerable, reduce dose How to dose reduce daraxonrasib: Starting dose: 300 mg once daily First reduction: 200 mg once daily (one 100 mg + one 100 mg) Second reduction: 150 mg once daily (one 150 mg) No further reduction below 150 mg Permanently discontinue if unable to tolerate 150 mg This ladder applies to adverse reactions; drug-interaction dose adjustments are different.
                            • Ongoing daraxonrasib monitoring at the tolerated dose
                              Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                          • Permanently discontinue daraxonrasib when required by toxicity-specific label guidance
                            Permanent discontinuation is required for specified severe or recurrent toxicities and when 150 mg once daily cannot be tolerated. Follow the toxicity-specific prescribing information.
                        • Continue daraxonrasib at current dose
                          • Ongoing daraxonrasib monitoring at the tolerated dose
                            Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                  • Diarrhea. 67% overall; Grade 3–4 7%: assess hydration and oral intake
                    Diarrhea, nausea, vomiting, abdominal pain. Assess grade and impact. Assess stool frequency, duration, oral intake, hydration and clinically relevant electrolyte or renal abnormalities. Median time to first onset: 3 days.
                    • Start loperamide (4 mg initially, then 2 mg) + hydration; modify daraxonrasib by grade
                      Start antidiarrheal therapy promptly. Supportive regimen: • Loperamide 4 mg initially, then 2 mg after each loose stool; maximum 16 mg/day. • Maintain oral or IV hydration and replace electrolytes as clinically indicated. • Add antiemetics as needed. Daraxonrasib modification: • Grade 2 persistent or intolerable: consider withholding until recovery to ≤Grade 1; resume at the same or next lower dose. • Grade 3: withhold until recovery to ≤Grade 1; resume at the next lower dose. • Grade 4: permanently discontinue.
                      • Does label guidance require treatment interruption or dose modification?
                        Applies to any toxicity requiring hold. Refer to dose reduction rules below.
                        • After recovery, which label-directed daraxonrasib disposition applies?
                          Most toxicity-specific restart criteria require recovery to ≤Grade 1; for other Grade 3 adverse reactions, recovery to ≤Grade 1 or baseline is required. Select the disposition specified for the toxicity and grade.
                          • Resume daraxonrasib at the current dose when label guidance permits
                            Applicable to selected Grade 2 rash, stomatitis or diarrhea after recovery to ≤Grade 1 when resumption at the same dose is clinically appropriate.
                            • Ongoing daraxonrasib monitoring at the tolerated dose
                              Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                          • Resume one dose level lower — 300 → 200 → 150 mg once daily
                            If recurrence or grade ≥2 intolerable, reduce dose How to dose reduce daraxonrasib: Starting dose: 300 mg once daily First reduction: 200 mg once daily (one 100 mg + one 100 mg) Second reduction: 150 mg once daily (one 150 mg) No further reduction below 150 mg Permanently discontinue if unable to tolerate 150 mg This ladder applies to adverse reactions; drug-interaction dose adjustments are different.
                            • Ongoing daraxonrasib monitoring at the tolerated dose
                              Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                          • Permanently discontinue daraxonrasib when required by toxicity-specific label guidance
                            Permanent discontinuation is required for specified severe or recurrent toxicities and when 150 mg once daily cannot be tolerated. Follow the toxicity-specific prescribing information.
                        • Continue daraxonrasib at current dose
                          • Ongoing daraxonrasib monitoring at the tolerated dose
                            Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                  • Suspected ILD/pneumonitis or GI perforation. HOLD daraxonrasib and urgently evaluate
                    New or worsening dyspnea, cough or fever: • Withhold daraxonrasib and evaluate for ILD/pneumonitis. Severe or persistent abdominal pain or clinical concern for perforation: • Withhold daraxonrasib and urgently evaluate for gastrointestinal perforation. ILD/pneumonitis: • Grade 2: hold to ≤Grade 1; if appropriate, resume one dose lower. • Recurrent Grade 2 or Grade 3–4: permanently discontinue. GI perforation: • Grade 3: hold to ≤Grade 1; if appropriate, resume one dose lower. • Grade 4: permanently discontinue.
                    • Does label guidance require treatment interruption or dose modification?
                      Applies to any toxicity requiring hold. Refer to dose reduction rules below.
                      • After recovery, which label-directed daraxonrasib disposition applies?
                        Most toxicity-specific restart criteria require recovery to ≤Grade 1; for other Grade 3 adverse reactions, recovery to ≤Grade 1 or baseline is required. Select the disposition specified for the toxicity and grade.
                        • Resume daraxonrasib at the current dose when label guidance permits
                          Applicable to selected Grade 2 rash, stomatitis or diarrhea after recovery to ≤Grade 1 when resumption at the same dose is clinically appropriate.
                          • Ongoing daraxonrasib monitoring at the tolerated dose
                            Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                        • Resume one dose level lower — 300 → 200 → 150 mg once daily
                          If recurrence or grade ≥2 intolerable, reduce dose How to dose reduce daraxonrasib: Starting dose: 300 mg once daily First reduction: 200 mg once daily (one 100 mg + one 100 mg) Second reduction: 150 mg once daily (one 150 mg) No further reduction below 150 mg Permanently discontinue if unable to tolerate 150 mg This ladder applies to adverse reactions; drug-interaction dose adjustments are different.
                          • Ongoing daraxonrasib monitoring at the tolerated dose
                            Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                        • Permanently discontinue daraxonrasib when required by toxicity-specific label guidance
                          Permanent discontinuation is required for specified severe or recurrent toxicities and when 150 mg once daily cannot be tolerated. Follow the toxicity-specific prescribing information.
                      • Continue daraxonrasib at current dose
                        • Ongoing daraxonrasib monitoring at the tolerated dose
                          Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                  • Grade ≥3 laboratory or other clinically significant toxicity. Evaluate cause and severity
                    Evaluate relevant laboratory abnormalities and alternative/contributing causes, including disease-related factors, dehydration and concomitant medications. Grade according to CTCAE v5.0. Transaminase ↑, bilirubin ↑, cytopenias. Assess grade and trends.
                    • Other Grade 3 toxicity: hold to ≤G1/baseline + lower dose; Grade 4: discontinue
                      Grade 3: • Withhold daraxonrasib until recovery to ≤Grade 1 or baseline. • Resume at the next lower dose. Grade 4: • Permanently discontinue. Address reversible or competing causes before resumption when clinically appropriate.
                      • Does label guidance require treatment interruption or dose modification?
                        Applies to any toxicity requiring hold. Refer to dose reduction rules below.
                        • After recovery, which label-directed daraxonrasib disposition applies?
                          Most toxicity-specific restart criteria require recovery to ≤Grade 1; for other Grade 3 adverse reactions, recovery to ≤Grade 1 or baseline is required. Select the disposition specified for the toxicity and grade.
                          • Resume daraxonrasib at the current dose when label guidance permits
                            Applicable to selected Grade 2 rash, stomatitis or diarrhea after recovery to ≤Grade 1 when resumption at the same dose is clinically appropriate.
                            • Ongoing daraxonrasib monitoring at the tolerated dose
                              Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                          • Resume one dose level lower — 300 → 200 → 150 mg once daily
                            If recurrence or grade ≥2 intolerable, reduce dose How to dose reduce daraxonrasib: Starting dose: 300 mg once daily First reduction: 200 mg once daily (one 100 mg + one 100 mg) Second reduction: 150 mg once daily (one 150 mg) No further reduction below 150 mg Permanently discontinue if unable to tolerate 150 mg This ladder applies to adverse reactions; drug-interaction dose adjustments are different.
                            • Ongoing daraxonrasib monitoring at the tolerated dose
                              Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                          • Permanently discontinue daraxonrasib when required by toxicity-specific label guidance
                            Permanent discontinuation is required for specified severe or recurrent toxicities and when 150 mg once daily cannot be tolerated. Follow the toxicity-specific prescribing information.
                        • Continue daraxonrasib at current dose
                          • Ongoing daraxonrasib monitoring at the tolerated dose
                            Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                • No
                  • Continue daraxonrasib at current dose
                    • Ongoing daraxonrasib monitoring at the tolerated dose
                      Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
  2. Patient instructions: contact the care team early for rash, mouth sores, diarrhea, breathing symptoms or severe abdominal pain
    Report promptly: • New or worsening rash, painful skin, blistering or extensive skin symptoms • Mouth sores or difficulty eating/drinking • Persistent or worsening diarrhea • New cough, dyspnea or fever • Severe or persistent abdominal pain
  3. How to take daraxonrasib: 300 mg once daily, with or without food; swallow tablets whole
    Tablets are available as 100 mg and 150 mg. Take at the same time each day. Do not chew, crush or split tablets. Missed by >4 hours: skip the dose. Vomiting after a dose: do not repeat the dose.
  4. Dose Reduction Ladder
    Starting dose: 300 mg once daily First reduction: 200 mg once daily (one 100 mg + one 100 mg) Second reduction: 150 mg once daily (one 150 mg) No further reduction below 150 mg Permanently discontinue if 150 mg once daily is not tolerated. Drug-interaction adjustments use a separate label-directed dosing scheme.
  5. Key drug interactions
    Avoid strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, clarithromycin) → ↑ exposure Avoid strong CYP3A inducers (e.g., rifampin, carbamazepine, phenytoin, St John’s wort) → ↓ exposure Avoid strong P-gp inhibitors (e.g., quinidine, cyclosporine) Avoid strong P-gp inducers (e.g., rifampin) Esomeprazole 40 mg daily: no clinically significant PK change
  6. Adverse reactions: frequency and severity
    Rash: 87% | Grade 3–4: 13% Diarrhea: 67% | Grade 3–4: 7% Stomatitis: 56% | Grade 3–4: 12% Nausea: 52% | Grade 3–4: 3% Fatigue: 47% | Grade 3–4: 5% Vomiting: 42% | Grade 3–4: 1%
  7. Key red flags: hold and urgently evaluate
    New or worsening dyspnea, cough, fever → evaluate for ILD/pneumonitis Severe or persistent abdominal pain → evaluate for GI perforation Any grade ≥3 or life-threatening AE
  8. Hepatic impairment: mild/moderate exposure unchanged; severe impairment not established
    U.S. Prescribing Information: • Mild hepatic impairment: total bilirubin >ULN to 1.5×ULN, OR AST >ULN with normal bilirubin. • Moderate hepatic impairment: total bilirubin >1.5 to 3×ULN with any AST level. No clinically significant difference in daraxonrasib pharmacokinetics was observed with mild or moderate hepatic impairment. • Severe hepatic impairment: total bilirubin >3 to 10×ULN with any AST level. The effect of severe hepatic impairment on daraxonrasib pharmacokinetics is unknown.
tosprivacyFDA approves daraxonrasib for metastatic pancreatic adenocarcinoma. August 26, 2026.RASONQUE (daraxonrasib) Full Prescribing Information. Revolution Medicines. August 2026.NEJM PPT file - Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic CancerPDF file - Protocol for: O’Reilly EM, Wainberg ZA, Hendifar AE, et al. Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N Engl J Med 2026;395:325-37. DOI: 10.1056/NEJMoa2605555PDF file - Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic CancerRASolute 302. ClinicalTrials.gov NCT06625320.Common Terminology Criteria for Adverse Events, Version 5.0